Evidence map›Paper›PMID 39511411›Full record

ArticleOncogene2025

Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15.

Yuchun Niu, Yichun Tang, Feng Ma, Xuyang Zhou, Yi Chen, Yu Wang, Yue Xu, Lei Sun, Shaoqiang Liang, Jianqi Yang and 4 more

Abstract read
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026
    Review
  4. [Research Progress on the Role of Notch Signaling Pathway in Small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuchun Niu *Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yichun Tang *Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Feng Ma *Department of Radiation Oncology, The First People's Hospital of Foshan, Foshan, China.
Xuyang ZhouDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yi ChenDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yu WangDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yue XuDepartment of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
Lei SunDepartment of Oncology, The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China.
Shaoqiang LiangDepartment of Radiation Oncology, The First People's Hospital of Foshan, Foshan, China.
Jianqi YangDepartment of Orthopedics, The First People's Hospital of Foshan, Foshan, People's Republic of China.
Kai WangDepartment of Orthopedics, The First People's Hospital of Foshan, Foshan, People's Republic of China.
Fan ZhangDepartment of Pathology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. Fanzhang681@163.com.
Shan SuDepartment of Oncology, Guangzhou Chest Hospital, Guangzhou, China. susan705@126.com.
Linlang GuoDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. linlangg@yahoo.com.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81972809
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is an aggressive form of lung cancer that often becomes resistant to chemotherapy. Understanding the molecular mechanisms of chemoresistance is crucial for identifying effective therapeutic targets. In this study, we used RNA-Seq to identify highly expressed molecules associated with chemoresistance. We also performed H3K27Ac and ATAC-Seq binding analyses to identify super-enhancers (SE) and their corresponding transcription factors. Both in vitro and in vivo experiments were conducted to examine the impact of these molecules and clinical samples were collected to establish their prognostic value. Our findings revealed elevated expression of MYCNOS, which exhibited chemoresistant properties in both in vitro and in vivo models of SCLC. We identified MYCNOS-SE as a significant SE in SCLC that regulates the distal target gene MYCNOS. This SE recruits transcription factors CTCF and KLF15 to regulate MYCNOS expression. Additionally, MYCNOS, an antisense of MYCN, was found to modulate chemotherapy sensitivity through the NOTCH pathway. This study highlights the significance of SE -regulated target genes as markers for chemoresistance in SCLC. Furthermore, it suggests that MYCNOS could serve as a predictor to identify patients who may benefit from NOTCH inhibitors. These findings provide valuable insights for future studies aimed at developing therapeutic strategies targeting these identified pathways.

Indexed as

CCCTC-Binding FactorDrug Resistance, NeoplasmEnhancer Elements, GeneticKruppel-Like Transcription FactorsLung NeoplasmsN-Myc Proto-Oncogene ProteinSmall Cell Lung CarcinomaAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMicePrognosisXenograft Model Antitumor AssaysCCCTC-Binding FactorCTCF protein, humanKruppel-Like Transcription FactorsMYCN protein, humanN-Myc Proto-Oncogene Protein

Identifiers

PMID39511411
PMCPMC11746145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.